Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price Up 3.6% - Here's What Happened

Key Points

• Regeneron shares rose 3.6% to about $780.49, although trading volume was 54% below the average session volume.
• Analysts remain broadly positive, with a consensus “Moderate Buy” rating and an average price target of $834.24; several firms recently raised their targets.
• The company reported strong quarterly results, earning $14.29 per share versus the $10.16 estimate and generating $4.29 billion in revenue, up 16.7% year over year.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Get Free Report)'s share price rose 3.6% during trading on Wednesday. The stock traded as high as $779.67 and last traded at $780.4880. Approximately 375,131 shares changed hands during trading, a decline of 54% from the average session volume of 819,843 shares. The stock had previously closed at $753.12.

Analyst Upgrades and Downgrades

REGN has been the topic of several recent analyst reports. Weiss Ratings reissued a "hold (c)" rating on shares of Regeneron Pharmaceuticals in a research note on Monday, September 21st. Guggenheim raised their price objective on shares of Regeneron Pharmaceuticals from $1,000.00 to $1,030.00 and gave the stock a "buy" rating in a research report on Monday, August 3rd. Leerink Partners lifted their price objective on shares of Regeneron Pharmaceuticals from $641.00 to $824.00 and gave the company a "market perform" rating in a research note on Monday, August 17th. Jefferies Financial Group boosted their target price on shares of Regeneron Pharmaceuticals from $870.00 to $930.00 and gave the company a "buy" rating in a research report on Thursday, October 1st. Finally, Wells Fargo & Company boosted their target price on shares of Regeneron Pharmaceuticals from $700.00 to $750.00 and gave the company an "equal weight" rating in a research report on Friday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and nine have given a Hold rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $834.24.

Regeneron Pharmaceuticals Price Performance

The business has a 50-day moving average of $790.91 and a 200 day moving average of $720.73. The company has a current ratio of 3.34, a quick ratio of 2.78 and a debt-to-equity ratio of 0.06. The firm has a market capitalization of $80.04 billion, a P/E ratio of 19.22, a price-to-earnings-growth ratio of 1.38 and a beta of 0.16.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $10.16 by $4.13. Regeneron Pharmaceuticals had a return on equity of 13.47% and a net margin of 27.86%. The business had revenue of $4.29 billion for the quarter, compared to analyst estimates of $3.82 billion. During the same quarter in the prior year, the company earned $12.81 earnings per share. The company's quarterly revenue was up 16.7% on a year-over-year basis. On average, sell-side analysts predict that Regeneron Pharmaceuticals, Inc. will post 47.93 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Monday, August 31st. Investors of record on Tuesday, August 18th were given a $0.94 dividend. The ex-dividend date of this dividend was Tuesday, August 18th. This represents a $3.76 annualized dividend and a yield of 0.5%. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is presently 9.29%.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, Director Huda Zoghbi sold 800 shares of the business's stock in a transaction on Monday, August 10th. The shares were sold at an average price of $800.00, for a total transaction of $640,000.00. Following the completion of the sale, the director owned 1,703 shares in the company, valued at approximately $1,362,400. The trade was a 31.96% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kathryn Guarini sold 400 shares of the company's stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $850.00, for a total transaction of $340,000.00. Following the transaction, the director owned 603 shares in the company, valued at approximately $512,550. The trade was a 39.88% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 3,946 shares of company stock worth $3,302,458. 6.97% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Regeneron Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in REGN. Seelaus Asset Management LLC lifted its position in Regeneron Pharmaceuticals by 17.6% in the 3rd quarter. Seelaus Asset Management LLC now owns 589 shares of the biopharmaceutical company's stock valued at $447,000 after acquiring an additional 88 shares in the last quarter. First Citizens Bank & Trust Co. purchased a new stake in shares of Regeneron Pharmaceuticals in the third quarter worth approximately $1,730,000. Signal Advisors Wealth LLC bought a new position in shares of Regeneron Pharmaceuticals in the third quarter valued at approximately $201,000. B. Riley Wealth Advisors Inc. lifted its holdings in shares of Regeneron Pharmaceuticals by 49.8% in the third quarter. B. Riley Wealth Advisors Inc. now owns 620 shares of the biopharmaceutical company's stock valued at $470,000 after purchasing an additional 206 shares in the last quarter. Finally, Krilogy Financial LLC lifted its holdings in shares of Regeneron Pharmaceuticals by 31.7% in the third quarter. Krilogy Financial LLC now owns 2,474 shares of the biopharmaceutical company's stock valued at $1,887,000 after purchasing an additional 596 shares in the last quarter. Institutional investors and hedge funds own 83.31% of the company's stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses human genetics, antibody technology and other biological research platforms to develop treatments in areas including eye diseases, cancer, cardiovascular and metabolic disorders, inflammatory diseases, infectious diseases and rare conditions.

Regeneron's marketed products include EYLEA and EYLEA HD for certain retinal diseases; Dupixent, developed and commercialized with Sanofi, for multiple allergic and inflammatory conditions; Libtayo for certain cancers; Praluent for high cholesterol; Kevzara for rheumatoid arthritis and other inflammatory diseases; Evkeeza for homozygous familial hypercholesterolemia; and Veopoz for a rare immune-mediated disorder.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.